Preliminary findings show that 45 study volunteers who received either a low or medium dose had immune response
WEDNESDAY, July 1, 2020 (HealthDay News) — An experimental COVID-19 vaccine yielded promising results in early testing, according to Pfizer and its German partner BioNTech.
Preliminary findings show that the 45 study volunteers who received either a low or medium dose, in two shots about a month apart, had immune responses in the range expected to protect against the disease, the Associated Press reported.
The results have been submitted for publication in a scientific journal but not yet reviewed.
Pfizer and BioNTech are working on four experimental vaccines. About 15 different COVID-19 vaccine candidates are in human testing worldwide, with several poised to begin large, last-stage studies to determine if they are actually effective, the AP reported.
Copyright © 2020 HealthDay. All rights reserved.
